🔎 Trials Near Me

Home › Neuroblastoma › Utah

Pag-aaral pangklinika para sa Neuroblastoma sa Utah

6 pag-aaral para sa Neuroblastoma ang naghahanap ng mga kalahok sa mga site sa Utah.

Mga Lungsod sa Utah

Opisyal na teksto ng pag-aaral (English)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Primary Children's Hospital, Salt Lake City
Nagre-recruitPhase 3
Hanggang edad 30 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06172296

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Primary Children's Hospital, Salt Lake City
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06541262

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Primary Children's Hospital, Salt Lake City
Nagre-recruitPhase 3
365 Days – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03126916

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • University of Utah Hospital, Salt Lake City
Nagre-recruitPhase 1/2
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06721689

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Primary Children's Hospital, Salt Lake City
Nagre-recruitPhase 2
18 Months – 40 Years · Lahat ng kasarian · Na-update Ago 12, 2025 · NCT05135975

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.